[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573132":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Hospital Authority, Hong Kong","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Faricimab treatment arm","ACTIVE_COMPARATOR","A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. The intervention faricimab is injected into the eyeball with a 30G needle.",[13],"Drug: Faricimab Injection [Vabysmo]",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Faricimab Injection [Vabysmo]","A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Daniel Ho Tak Wong, FRCOphth (UK)","CONTACT","+852 3949 3411","WHT454@ha.org.hk",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Department of Ophthalmology, United Chrisitian Hospital","RECRUITING","Hong Kong","HK",{"type":34,"coordinates":35},"Point",[36,37],114.17469,22.27832,{"lat":37,"lon":36},[40],{"name":41,"role":24,"phone":25,"phoneExt":20,"email":42},"Suzy Wong","wnp391@ha.org.hk",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Wong Ho Daniel Tak","Principal Investigator","100573132","phase-4-faricimab-quarterly-maintenance-for-neovascular-age-related-macular-degeneration-100573132",false,"NCT06742307","Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration","Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series","Fixed farcimab","Inclusion Criteria:\n\nSubjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3.\n\nExclusion Criteria:\n\n* eyes that received any anti-VEGF therapy in the prior six months,\n* eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation),\n* concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period.","ALL","50 Years",{"count":58,"type":59},40,"ESTIMATED","INTERVENTIONAL",[62],"PHASE4","We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.",[65],"Macular Degeneration Choroidal Neovascularization",[67,68],"neovascular age related macular degeneration","faricimab","2025-09-26",{"date":71,"type":72},"2025-10-01","ACTUAL",{"date":74,"type":72},"2025-08-21",{"date":76,"type":59},"2027-02-01",{"name":5,"class":6},1]